In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1835 News Items found
Postdoctoral researcher Yanan Ma, PhD
Go Fish: Why MSK Researchers Use Zebrafish To Study a Cancer-Linked Inflammation Pathway

A study led by postdoctoral researcher Yanan Ma from the lab of cell biologist Philipp Niethammer shows why diversity also matters in model animal research.
Boris Mueller, MD, Director, Radiation Oncology at MSK Bergen is seen standing in a hallway.
Breast Cancer and Tattoo-Less Radiation at MSK

Learn how people with early stage breast cancer can receive radiation therapy without the need for tattoos at Memorial Sloan Kettering Cancer Center.
Attendees of the fifth annual MSK-CTONG Symposium
Memorial Sloan Kettering and the Chinese Thoracic Oncology Group Urge International Harmonization to Accelerate Cancer Drug Approvals at Annual Event

Global regulatory harmonization of clinical trials provides significant opportunity to accelerate access to cancer treatments to benefit all of humanity. This was the theme of the fifth annual MSK-CTONG Symposium, hosted online for a global audience of 20,000 from Guangzhou, China and New York on December 2, 2022.
detail shot of laboratory slides
MSK Research Highlights, December 23, 2022

New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute explores ways to limit heart damage from chemotherapy and radiation; examines genomic differences between primary and metastatic tumors in bladder cancer; aims to understand the safety of check point inhibitor therapy for patients who are obese; and investigates a potential therapeutic approach against acute myeloid leukemia.
Feature
x-ray of bladder with large tumor
Bladder Preservation in Muscle-Invasive Bladder Cancer Based on DDR Genetic Mutations

MSK researchers are investigating a new way that people with bladder cancer can avoid bladder removal.
In the Lab
Dmitriy Zamarin and Sohrab Shah
MSK Team Focuses on Resistance to Immunotherapy in Ovarian Cancer

A collaborative team from MSK has uncovered important new findings that explain why ovarian cancer does not respond to immunotherapy.
Person in white lab coat using a pipette with a tiny test tube.
Top Cancer Research Advances at MSK in 2022

Read about some of the biggest scientific discoveries made by MSK researchers in 2022.
Feature
(Left to right) Sascha Roth, Luis Diaz, Imtiaz Hussain, Andrea Cercek, Avery Holmes, and Nisha Varughese.
Top Cancer Treatment Advances at MSK in 2022

Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Here are some of the most important developments.
MSK bile duct cancer patient Berta Pesantez
How MSK Is Making Cancer Clinical Trials in NYC Easier To Access

For many patients, time is of the essence. At MSK, patients have access to potentially lifesaving therapies long before they are available at community hospitals. Learn how MSK’s Cancer Health Equity Research Program (CHERP) partners with a network of public hospitals in New York City to recruit underserved patients for clinical trials at MSK and give them access to world-class care.
Blood samples being prepared for a centrifuge
MSK Research Highlights, ASH Annual Meeting 2022

Numerous developments in cellular therapy, multiple myeloma, leukemia and lymphoma are being presented by Memorial Sloan Kettering Cancer Center (MSK) researchers at the American Society of Hematology (ASH) Annual Meeting, which runs December 10-13.